These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11072043)

  • 21. A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure With Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized With Serotype A Antitoxin.
    Maslanka SE; Lúquez C; Dykes JK; Tepp WH; Pier CL; Pellett S; Raphael BH; Kalb SR; Barr JR; Rao A; Johnson EA
    J Infect Dis; 2016 Feb; 213(3):379-85. PubMed ID: 26068781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An in vitro cell-based potency assay for pharmaceutical type A botulinum antitoxins.
    Torgeman A; Diamant E; Levin L; David AB; Epstein E; Girshengorn M; Mazor O; Rosenfeld R; Zichel R
    Vaccine; 2017 Dec; 35(52):7213-7216. PubMed ID: 29174678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F.
    Yu YZ; Zhang SM; Ma Y; Zhu HQ; Wang WB; Du Y; Zhou XW; Wang RL; Wang S; Yu WY; Huang PT; Sun ZW
    Clin Immunol; 2010 Nov; 137(2):271-80. PubMed ID: 20696619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Standardization of the Japanese National Standard, Equine Botulinum Antitoxin Type A, and Factors Affecting Standardization.
    Yutani M; Senoh M; Yano H; Kenri T; Iwaki M
    Jpn J Infect Dis; 2024 Jan; 77(1):16-20. PubMed ID: 37648491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botulinum neurotoxin serotype A inhibitors: small-molecule mercaptoacetamide analogs.
    Moe ST; Thompson AB; Smith GM; Fredenburg RA; Stein RL; Jacobson AR
    Bioorg Med Chem; 2009 Apr; 17(8):3072-9. PubMed ID: 19329331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proper dose, preparation, and storage of botulinum neurotoxin serotype A.
    Anderson ER
    Am J Health Syst Pharm; 2004 Nov; 61(22 Suppl 6):S24--9. PubMed ID: 15598006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antagonism of the paralysis produced by botulinum toxin in the rat. The effects of tetraethylammonium, guanidine and 4-aminopyridine.
    Lundh H; Leander S; Thesleff S
    J Neurol Sci; 1977 May; 32(1):29-43. PubMed ID: 194021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of
    Bano L; Tonon E; Drigo I; Pirazzini M; Guolo A; Farina G; Agnoletti F; Montecucco C
    Toxins (Basel); 2018 Jun; 10(6):. PubMed ID: 29921757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Uptake of botulinum neurotoxin into cultured neurons.
    Keller JE; Cai F; Neale EA
    Biochemistry; 2004 Jan; 43(2):526-32. PubMed ID: 14717608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model.
    Mukherjee J; Tremblay JM; Leysath CE; Ofori K; Baldwin K; Feng X; Bedenice D; Webb RP; Wright PM; Smith LA; Tzipori S; Shoemaker CB
    PLoS One; 2012; 7(1):e29941. PubMed ID: 22238680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recovery from botulinum neurotoxin poisoning in vivo.
    Keller JE
    Neuroscience; 2006 May; 139(2):629-37. PubMed ID: 16490322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Type A1 but not type A2 botulinum toxin decreases the grip strength of the contralateral foreleg through axonal transport from the toxin-treated foreleg of rats.
    Torii Y; Akaike N; Harakawa T; Kato K; Sugimoto N; Goto Y; Nakahira S; Kohda T; Kozaki S; Kaji R; Ginnaga A
    J Pharmacol Sci; 2011; 117(4):275-85. PubMed ID: 22123262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phrenic nerve-hemidiaphragm as a highly sensitive replacement assay for determination of functional botulinum toxin antibodies.
    Rasetti-Escargueil C; Liu Y; Rigsby P; Jones RG; Sesardic D
    Toxicon; 2011 Jun; 57(7-8):1008-16. PubMed ID: 21513727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The life history of a botulinum toxin molecule.
    Simpson L
    Toxicon; 2013 Jun; 68():40-59. PubMed ID: 23518040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mouse compound muscle action potential assay: an alternative method to conduct the LD₅₀ botulinum toxin type A potency test.
    Kim SH; Kim SB; Yang GH; Rhee CH
    Toxicon; 2012 Sep; 60(3):341-7. PubMed ID: 22613167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E.
    Hatheway CH; Snyder JD; Seals JE; Edell TA; Lewis GE
    J Infect Dis; 1984 Sep; 150(3):407-12. PubMed ID: 6481185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of Monoclonal Antibodies in the Sensitive Detection and Neutralization of Botulinum Neurotoxin Serotype B.
    Cheng LW; Henderson TD; Lam TI; Stanker LH
    Toxins (Basel); 2015 Nov; 7(12):5068-78. PubMed ID: 26633496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Purification and Characterization of Botulinum Neurotoxin FA from a Genetically Modified Clostridium botulinum Strain.
    Pellett S; Tepp WH; Bradshaw M; Kalb SR; Dykes JK; Lin G; Nawrocki EM; Pier CL; Barr JR; Maslanka SE; Johnson EA
    mSphere; 2016; 1(1):. PubMed ID: 27303710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Study on the immunological heterogeneity of Clostridium botulinum B type toxin.
    Rymkiewicz D; Sawicki J; Brühl A
    Arch Immunol Ther Exp (Warsz); 1979; 27(5):709-14. PubMed ID: 398207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Botulinum toxin type A: kinetics of calcium dependent paralysis of the neuromuscular junction and antagonism by drugs and animal toxins.
    Metezeau P; Desban M
    Toxicon; 1982; 20(3):649-54. PubMed ID: 6125045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.